Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Colistin | 6 | 2019 | 217 | 2.66 | Why? |
| Pseudomonas Infections | 5 | 2019 | 425 | 1.71 | Why? |
| Pseudomonas aeruginosa | 6 | 2019 | 652 | 1.40 | Why? |
| Urinary Tract Infections | 5 | 2019 | 534 | 1.28 | Why? |
| Anti-Bacterial Agents | 14 | 2019 | 10083 | 1.02 | Why? |
| Prosthesis-Related Infections | 4 | 2017 | 302 | 0.88 | Why? |
| Joint Prosthesis | 1 | 2017 | 20 | 0.69 | Why? |
| Bronchitis | 1 | 2019 | 146 | 0.68 | Why? |
| Daptomycin | 1 | 2017 | 64 | 0.65 | Why? |
| Drug Resistance, Multiple, Bacterial | 5 | 2019 | 1115 | 0.62 | Why? |
| Rifampin | 2 | 2017 | 276 | 0.61 | Why? |
| Salvage Therapy | 2 | 2017 | 417 | 0.59 | Why? |
| Pneumonia, Bacterial | 2 | 2019 | 843 | 0.57 | Why? |
| Staphylococcal Infections | 2 | 2019 | 1099 | 0.37 | Why? |
| Renal Insufficiency, Chronic | 3 | 2020 | 2654 | 0.37 | Why? |
| Plasma | 1 | 2016 | 1809 | 0.31 | Why? |
| Chromatography, High Pressure Liquid | 3 | 2017 | 669 | 0.28 | Why? |
| Escherichia coli Infections | 3 | 2017 | 348 | 0.27 | Why? |
| Gram-Negative Bacterial Infections | 2 | 2018 | 398 | 0.24 | Why? |
| Metabolomics | 2 | 2018 | 921 | 0.23 | Why? |
| Penicillanic Acid | 2 | 2018 | 58 | 0.22 | Why? |
| Drug Administration Schedule | 2 | 2019 | 2324 | 0.22 | Why? |
| Escherichia coli | 3 | 2017 | 1547 | 0.21 | Why? |
| Cephalosporins | 2 | 2018 | 250 | 0.19 | Why? |
| Pyelonephritis | 2 | 2018 | 66 | 0.18 | Why? |
| Linezolid | 1 | 2019 | 160 | 0.18 | Why? |
| Drug Resistance, Multiple | 1 | 2019 | 156 | 0.18 | Why? |
| Boronic Acids | 1 | 2018 | 30 | 0.18 | Why? |
| Biofilms | 2 | 2018 | 304 | 0.18 | Why? |
| Saccharomyces boulardii | 1 | 2017 | 5 | 0.18 | Why? |
| Thienamycins | 1 | 2018 | 72 | 0.18 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.17 | Why? |
| Drug Dosage Calculations | 1 | 2019 | 243 | 0.17 | Why? |
| Arthroplasty, Replacement | 1 | 2017 | 47 | 0.16 | Why? |
| Acute Kidney Injury | 1 | 2016 | 5762 | 0.16 | Why? |
| DNA Methylation | 1 | 2021 | 688 | 0.15 | Why? |
| Arthritis, Infectious | 1 | 2017 | 111 | 0.15 | Why? |
| Biological Availability | 1 | 2017 | 388 | 0.15 | Why? |
| Blood Sedimentation | 1 | 2017 | 508 | 0.14 | Why? |
| Spain | 11 | 2021 | 15545 | 0.14 | Why? |
| Virulence | 3 | 2018 | 2172 | 0.14 | Why? |
| Acinetobacter Infections | 1 | 2017 | 273 | 0.13 | Why? |
| Nephrology | 1 | 2020 | 546 | 0.13 | Why? |
| beta-Lactamases | 3 | 2018 | 759 | 0.13 | Why? |
| Streptococcal Infections | 1 | 2017 | 255 | 0.13 | Why? |
| Gram-Negative Bacteria | 1 | 2018 | 473 | 0.13 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.13 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2018 | 2984 | 0.13 | Why? |
| Zinc | 1 | 2021 | 817 | 0.13 | Why? |
| Klebsiella | 1 | 2012 | 35 | 0.13 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.13 | Why? |
| Aged | 21 | 2021 | 215776 | 0.12 | Why? |
| Renal Dialysis | 2 | 2020 | 4358 | 0.12 | Why? |
| Administration, Intravenous | 1 | 2017 | 1115 | 0.12 | Why? |
| Glomerular Filtration Rate | 1 | 2019 | 1262 | 0.12 | Why? |
| Drug Monitoring | 2 | 2019 | 1408 | 0.12 | Why? |
| Aged, 80 and over | 10 | 2020 | 88759 | 0.11 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.11 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2019 | 861 | 0.11 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.11 | Why? |
| Aspergillus | 1 | 2014 | 347 | 0.11 | Why? |
| Intestines | 1 | 2017 | 817 | 0.11 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.10 | Why? |
| Patient Readmission | 1 | 2019 | 1543 | 0.10 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.10 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.10 | Why? |
| Female | 24 | 2021 | 380317 | 0.10 | Why? |
| Male | 22 | 2021 | 367725 | 0.10 | Why? |
| Probiotics | 1 | 2017 | 694 | 0.09 | Why? |
| Mannose-Binding Lectin | 1 | 2008 | 131 | 0.09 | Why? |
| Liver Cirrhosis | 1 | 2019 | 1810 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Klebsiella Infections | 1 | 2012 | 466 | 0.08 | Why? |
| Kidney Transplantation | 2 | 2020 | 5397 | 0.08 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 634 | 0.08 | Why? |
| Microbiota | 1 | 2017 | 1240 | 0.08 | Why? |
| Humans | 34 | 2021 | 930598 | 0.08 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.07 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.07 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.07 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2008 | 323 | 0.07 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Influenza, Human | 2 | 2018 | 10779 | 0.06 | Why? |
| Ciprofloxacin | 2 | 2018 | 130 | 0.06 | Why? |
| Bacteremia | 1 | 2012 | 1372 | 0.06 | Why? |
| Escherichia coli Proteins | 1 | 2002 | 168 | 0.06 | Why? |
| Adult | 12 | 2021 | 244371 | 0.06 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.05 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.05 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.05 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.05 | Why? |
| Hospitals | 2 | 2018 | 11793 | 0.05 | Why? |
| CpG Islands | 1 | 2021 | 230 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.05 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.05 | Why? |
| Polymyxins | 1 | 2017 | 8 | 0.05 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.05 | Why? |
| Piperacillin | 1 | 2018 | 63 | 0.05 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.04 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.04 | Why? |
| Hemodialysis Units, Hospital | 1 | 2020 | 195 | 0.04 | Why? |
| Hospitals, University | 2 | 2020 | 4173 | 0.04 | Why? |
| Aminoglycosides | 1 | 2017 | 94 | 0.04 | Why? |
| Ceftazidime | 1 | 2018 | 134 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Synovial Fluid | 1 | 2017 | 64 | 0.04 | Why? |
| Glycosylation | 1 | 2021 | 1255 | 0.04 | Why? |
| Genes, Bacterial | 1 | 2017 | 207 | 0.04 | Why? |
| Debridement | 1 | 2017 | 172 | 0.04 | Why? |
| beta-Lactam Resistance | 1 | 2017 | 150 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2018 | 673 | 0.04 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.04 | Why? |
| Streptococcus agalactiae | 1 | 2017 | 194 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Portugal | 1 | 2021 | 1265 | 0.04 | Why? |
| Nebulizers and Vaporizers | 1 | 2019 | 497 | 0.04 | Why? |
| Comorbidity | 4 | 2020 | 34796 | 0.04 | Why? |
| Cell Survival | 1 | 2021 | 1581 | 0.04 | Why? |
| Urine | 1 | 2018 | 469 | 0.04 | Why? |
| beta-Lactams | 1 | 2017 | 210 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Microbiological Techniques | 1 | 2017 | 232 | 0.04 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.03 | Why? |
| Placebos | 1 | 2017 | 629 | 0.03 | Why? |
| Chronic Disease | 2 | 2020 | 5139 | 0.03 | Why? |
| Acinetobacter baumannii | 1 | 2017 | 378 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2021 | 1648 | 0.03 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2019 | 1647 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 711 | 0.03 | Why? |
| Metabolome | 1 | 2017 | 624 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.03 | Why? |
| Candida | 1 | 2017 | 425 | 0.03 | Why? |
| Tertiary Care Centers | 2 | 2021 | 8248 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.03 | Why? |
| Adolescent | 3 | 2019 | 86841 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2017 | 1031 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Anti-Infective Agents | 1 | 2002 | 1766 | 0.03 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.03 | Why? |
| Patient Education as Topic | 1 | 2020 | 1476 | 0.03 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.02 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.02 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Cross Infection | 2 | 2020 | 8675 | 0.02 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.02 | Why? |
| Disinfection | 1 | 2020 | 2912 | 0.02 | Why? |
| Occupational Stress | 1 | 2020 | 2044 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.02 | Why? |
| Personal Protective Equipment | 2 | 2020 | 15978 | 0.02 | Why? |
| Early Diagnosis | 1 | 2014 | 2443 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Liver Diseases | 1 | 2020 | 2698 | 0.02 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Internationality | 1 | 2017 | 3297 | 0.02 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Nalidixic Acid | 1 | 2002 | 6 | 0.02 | Why? |
| Fimbriae, Bacterial | 1 | 2002 | 14 | 0.02 | Why? |
| Hemolysin Proteins | 1 | 2002 | 21 | 0.02 | Why? |
| Antifungal Agents | 1 | 2014 | 1828 | 0.02 | Why? |
| Cytotoxins | 1 | 2002 | 57 | 0.02 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3832 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.02 | Why? |
| Cystitis | 1 | 2002 | 45 | 0.02 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Asthma | 1 | 2020 | 4383 | 0.01 | Why? |
| Bacterial Toxins | 1 | 2002 | 185 | 0.01 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.01 | Why? |
| Animals | 2 | 2021 | 78931 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Survival Analysis | 1 | 2012 | 7592 | 0.01 | Why? |
| Heart Failure | 1 | 2020 | 6638 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2014 | 9537 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Drug Resistance, Microbial | 1 | 2002 | 419 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Critical Illness | 1 | 2019 | 17281 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2014 | 6331 | 0.01 | Why? |
| Disease Susceptibility | 1 | 2008 | 4002 | 0.01 | Why? |
| Registries | 1 | 2014 | 12327 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.01 | Why? |
| Infant, Newborn | 1 | 2012 | 23105 | 0.01 | Why? |
| Infant | 1 | 2012 | 30274 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Child, Preschool | 1 | 2012 | 36283 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Child | 1 | 2012 | 70012 | 0.00 | Why? |
Horcajada's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(215)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(200)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_